PRX-102 at Least as Effective as Fabrazyme, Interim Data Show

PRX-102 at Least as Effective as Fabrazyme, Interim Data Show

295876

PRX-102 at Least as Effective as Fabrazyme, Interim Data Show

One year of treatment with PRX-102 (pegunigalsidase alfa), an investigational enzyme replacement therapy (ERT), was at least as effective as Fabrazyme (agalsidase beta) at preventing kidney function decline in adults with Fabry disease, interim data from the BALANCE Phase 3 clinical trial show. These findings add to the growing body of clinical trial evidence supporting PRX-102, the first plant-based, every-other-week ERT, as a potential new treatment option for Fabry patients. “The BALANCE study continues as planned through…

You must be logged in to read/download the full post.